130 related articles for article (PubMed ID: 21788400)
1. Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit.
Maak M; Nitsche U; Keller L; Wolf P; Sarr M; Thiebaud M; Rosenberg R; Langer R; Kleeff J; Friess H; Johannes L; Janssen KP
Mol Cancer Ther; 2011 Oct; 10(10):1918-28. PubMed ID: 21788400
[TBL] [Abstract][Full Text] [Related]
2. Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit.
Geyer PE; Maak M; Nitsche U; Perl M; Novotny A; Slotta-Huspenina J; Dransart E; Holtorf A; Johannes L; Janssen KP
Mol Cancer Ther; 2016 May; 15(5):1008-17. PubMed ID: 26826119
[TBL] [Abstract][Full Text] [Related]
3. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool.
Falguières T; Maak M; von Weyhern C; Sarr M; Sastre X; Poupon MF; Robine S; Johannes L; Janssen KP
Mol Cancer Ther; 2008 Aug; 7(8):2498-508. PubMed ID: 18687997
[TBL] [Abstract][Full Text] [Related]
4. Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma.
Ehrenfeld M; Schrade A; Flisikowska T; Perl M; Hirsch ND; Sichler A; Geyer L; Flisikowski K; Wilhelm D; Schober SJ; Johannes L; Schnieke A; Janssen KP
Mol Cancer Ther; 2022 Apr; 21(4):686-699. PubMed ID: 35086950
[TBL] [Abstract][Full Text] [Related]
5. Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds.
Stimmer L; Dehay S; Nemati F; Massonnet G; Richon S; Decaudin D; Klijanienko J; Johannes L
BMC Cancer; 2014 Dec; 14():916. PubMed ID: 25476116
[TBL] [Abstract][Full Text] [Related]
6. Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer.
Distler U; Souady J; Hülsewig M; Drmić-Hofman I; Haier J; Friedrich AW; Karch H; Senninger N; Dreisewerd K; Berkenkamp S; Schmidt MA; Peter-Katalinić J; Müthing J
PLoS One; 2009 Aug; 4(8):e6813. PubMed ID: 19714252
[TBL] [Abstract][Full Text] [Related]
7. Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer.
Mohseni Z; Sedighian H; Halabian R; Amani J; Behzadi E; Imani Fooladi AA
Eur J Pharmacol; 2021 May; 899():174057. PubMed ID: 33753109
[TBL] [Abstract][Full Text] [Related]
8. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells.
Warnier M; Römer W; Geelen J; Lesieur J; Amessou M; van den Heuvel L; Monnens L; Johannes L
Kidney Int; 2006 Dec; 70(12):2085-91. PubMed ID: 17063173
[TBL] [Abstract][Full Text] [Related]
9. A real-time cell-binding assay reveals dynamic features of STxB-Gb3 cointernalization and STxB-mediated cargo delivery into cancer cells.
Encarnação JC; Napolitano V; Opassi G; Danielson UH; Dubin G; Popowicz GM; Munier-Lehmann H; Buijs J; Andersson K; Björkelund H
FEBS Lett; 2020 Aug; 594(15):2406-2420. PubMed ID: 32473599
[TBL] [Abstract][Full Text] [Related]
10. In vivo tumor targeting by the B-subunit of shiga toxin.
Viel T; Dransart E; Nemati F; Henry E; Thézé B; Decaudin D; Lewandowski D; Boisgard R; Johannes L; Tavitian B
Mol Imaging; 2008; 7(6):239-47. PubMed ID: 19123994
[TBL] [Abstract][Full Text] [Related]
11. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.
Adotevi O; Vingert B; Freyburger L; Shrikant P; Lone YC; Quintin-Colonna F; Haicheur N; Amessou M; Herbelin A; Langlade-Demoyen P; Fridman WH; Lemonnier F; Johannes L; Tartour E
J Immunol; 2007 Sep; 179(5):3371-9. PubMed ID: 17709554
[TBL] [Abstract][Full Text] [Related]
12. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.
Vingert B; Adotevi O; Patin D; Jung S; Shrikant P; Freyburger L; Eppolito C; Sapoznikov A; Amessou M; Quintin-Colonna F; Fridman WH; Johannes L; Tartour E
Eur J Immunol; 2006 May; 36(5):1124-35. PubMed ID: 16568496
[TBL] [Abstract][Full Text] [Related]
13. Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose Conjugation.
Liu Z; Li X; Lu Z; Qin X; Hong H; Zhou Z; Pieters RJ; Shi J; Wu Z
J Pharm Sci; 2022 Oct; 111(10):2719-2729. PubMed ID: 35905973
[TBL] [Abstract][Full Text] [Related]
14. Tissue penetration and activity of camptothecins in solid tumor xenografts.
Kyle AH; Baker JH; Gandolfo MJ; Reinsberg SA; Minchinton AI
Mol Cancer Ther; 2014 Nov; 13(11):2727-37. PubMed ID: 25143448
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract][Full Text] [Related]
16. Designing and Analyzing the Structure of DT-STXB Fusion Protein as an Anti-tumor Agent: An
Mohseni Moghadam Z; Halabian R; Sedighian H; Behzadi E; Amani J; Imani Fooladi AA
Iran J Pathol; 2019; 14(4):305-312. PubMed ID: 31754360
[TBL] [Abstract][Full Text] [Related]
17. Shiga toxin-mediated retrograde delivery of a topoisomerase I inhibitor prodrug.
El Alaoui A; Schmidt F; Amessou M; Sarr M; Decaudin D; Florent JC; Johannes L
Angew Chem Int Ed Engl; 2007; 46(34):6469-72. PubMed ID: 17645270
[No Abstract] [Full Text] [Related]
18. Shiga toxin glycosphingolipid receptor expression and toxin susceptibility of human pancreatic ductal adenocarcinomas of differing origin and differentiation.
Storck W; Meisen I; Gianmoena K; Pläger I; Kouzel IU; Bielaszewska M; Haier J; Mormann M; Humpf HU; Karch H; Müthing J
Biol Chem; 2012 Aug; 393(8):785-99. PubMed ID: 22944681
[TBL] [Abstract][Full Text] [Related]
19. Intracellular drug delivery: Potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy.
Luginbuehl V; Meier N; Kovar K; Rohrer J
Biotechnol Adv; 2018; 36(3):613-623. PubMed ID: 29432805
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
